RIN2
protein-codingRas and Rab interactor 2, the group of VPS9 domain containing
Gene summary
The RAB5 protein is a small GTPase involved in membrane trafficking in the early endocytic pathway. The protein encoded by this gene binds the GTP-bound form of the RAB5 protein preferentially over the GDP-bound form, and functions as a guanine nucleotide exchange factor for RAB5. The encoded protein is found primarily as a tetramer in the cytoplasm and does not bind other members of the RAB family. Mutations in this gene cause macrocephaly alopecia cutis laxa and scoliosis (MACS) syndrome, an elastic tissue disorder, as well as the related connective tissue disorder, RIN2 syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2011]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~244.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0013115
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0013115
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0013115
Submitter: ClinGen
RIN2 was first reported in relation to RIN2 syndrome (formerly MACS syndrome), an autosomal recessive lysosomal disease, in 2009 (Basel-Vanagaite L, et al.; PMID: 19631308). RIN2 encodes RAS and RAB interactor 2 and biallelic mutations in this gene are reported to cause cell trafficking dysfunction. Individuals with RIN2 syndrome have varying clinical features including macrocephaly, coarsening of facial features, down-slanting palpebral fissures, full everted lips, soft redundant skin, gum hypertrophy, irregular dentition, sparse scalp hair, joint hypermobility, and scoliosis. Four frameshift variants that have been reported in four probands in four publications (PMIDs: 19631308, 20424861, 24449201, 30769224) are included in this curation. In all cases, the variants presented in homozygosity. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity appears to be loss of function. This gene-disease relationship is also supported by expression studies that show this gene is expressed in fibroblasts, a relevant tissue, and studies showing that the expression level of the gene was markedly decreased when analyzed by qRT-PCR and absent when analyzed by immunoblotting (PMID: 19631308). In summary, there is definitive evidence supporting the relationship between RIN2 and autosomal recessive RIN2 syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Lysosomal Diseases GCEP on December 4, 2023 (SOP Version 9).
Inheritance Pattern: AR
Disease ID:MONDO:0013115
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0013115
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0013115
Submitter: Genomics England PanelApp
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Dental; Dermatologic; Musculoskeletal; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to RIN2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_018993.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 6 | 175 | 4 | 185 | ||
| missense | 288 | 20 | 6 | 314 | ||
| nonsense | 3 | 1 | 3 | 7 | ||
| start loss | 0 | |||||
| frameshift | 9 | 3 | 6 | 18 | ||
| splice donor/acceptor (+/-2bp) | 4 | 5 | 9 | |||
| Total | 12 | 8 | 308 | 195 | 10 | 533 |
Highest pathogenic variant AF is 0.0001482356
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_061866.1 | 11 | MANE Select | |
| Ensembl | ENSP00000255006.7 | 11 | MANE Select | |
| RefSeq | NP_001229510.1 | 12 | Standard | |
| RefSeq | NP_001365167.1 | 6 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Vesicle-mediated transport
- Membrane Trafficking
- Rab regulation of trafficking
- Posttranslational regulation of adherens junction stability and dissassembly
- RAB GEFs exchange GTP for GDP on RABs
Biological Process
- endocytosis
- small GTPase mediated signal transduction
- positive regulation of GTPase activity
Molecular Function
- GTPase activator activity
- Rab guanyl-nucleotide exchange factor activity
- GTPase regulator activity
Cellular Component
- cellular_component
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000255006
- Coding exons
- 12
- Length
- 115937
- Individuals with no LoFs
- 124622
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 18
- Defined
- 124640
- p
- 0.0000722
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.724 | 490 | 537 | 0.912 | 0.0000309 | 6122 |
| Missense (PolyPhen) | 145 | 196.94 | 0.73628 | 2313 | ||
| Synonymous | 0.365 | 223 | 230 | 0.969 | 0.0000147 | 1864 |
| Loss of Function | 3.65 | 12 | 35.4 | 0.339 | 0.00000179 | 442 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000065 | 0.000065 | rare |
| Latino/Admixed American | 0.000030 | 0.000029 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.000056 | 0.000056 | rare |
| Finnish | 0.000097 | 0.000093 | rare |
| European (Non-Finnish) | 0.000064 | 0.000062 | rare |
| South Asian | 0.00014 | 0.00013 | rare |
| Other | 0.00017 | 0.00017 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Ras effector protein. May function as an upstream activator and/or downstream effector for RAB5B in endocytic pathway. May function as a guanine nucleotide exchange (GEF) of RAB5B, required for activating the RAB5 proteins by exchanging bound GDP for free GTP. {ECO:0000269|PubMed:11733506}.;
Recessive Scores
- pRec
- 0.133
Intolerance Scores
- LoFtool
- 0.602
- RVIS EVS
- 0.52
- RVIS percentile EVS
- 80.4
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.584
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |